Please login to the form below

Not currently logged in
Email:
Password:

David Holliday joins Octapharma USA as VP commercial development

Moves from Baxter Bioscience to take up senior sales and marketing role in the US

David Holliday - Octapharma USAOctapharma USA has appointed Baxter Bioscience's former VP of global marketing operations and haemophilia as its new VP of commercial development.

David Holliday will lead all US product marketing, sales and commercial activities at Octapharma, along with co-ordinating its global portfolio development initiatives.

The company is the US affiliate of Swiss-headquartered Octapharma AG, which develops and manufactures human protein products.

Holliday spent eight years at Baxter, gaining US and international experience in management, sales, marketing and business development, and was responsible for several successful product launches.

Prior to his time at Baxter, he held leadership positions at both Novartis and Ciba-Geigy Pharmaceuticals.

“We are very excited to have David Holliday, a true global leader in our industry, join our senior management team,” said Octapharma's USA president, Flemming Nielsen.

“He joins Octapharma USA at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth.”

26th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics